Clinical Trials
16 trialsNCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT04868708 2025-03-04
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
Phase 2 Completed
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT02337491 2020-12-22
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01967810 2020-02-25
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
Phase 2 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT00846612 2019-09-30
Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
NYU Langone Health
Phase 1 Completed
NCT01031381 2016-08-30
RADBEV
University of Pittsburgh
Phase 2 Completed
NCT01113398 2015-12-10
AMG 102 and Avastin for Recurrent Malignant Glioma
Duke University
Phase 2 Completed
NCT00756340 2015-10-14
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00271609 2014-04-29
Bevacizumab for Recurrent Malignant Glioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01017250 2014-02-28
Radiosurgery and Avastin for Recurrent Malignant Gliomas
Duke University
Phase NA Completed
NCT00458731 2014-02-19
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00463203 2011-06-29
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Rigshospitalet, Denmark
Phase 2 Completed
NCT00095225 2008-01-29
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
Genentech, Inc.
Phase 2 Completed